Ono Pharmaceutical Co., Ltd.
OPHLY · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $746,857,462 | $1,185,926,627 | $4,042,675,603 | $4,514,730,211 |
| - Cash | $204,567,000 | $166,141,000 | $96,135,000 | $69,112,000 |
| + Debt | $146,678,000 | $8,862,000 | $9,168,000 | $8,802,000 |
| Enterprise Value | $688,968,462 | $1,028,647,627 | $3,955,708,603 | $4,454,420,211 |
| Revenue | $486,871,000 | $502,672,000 | $447,187,000 | $361,361,000 |
| % Growth | -3.1% | 12.4% | 23.8% | – |
| Gross Profit | $338,921,000 | $375,546,000 | $337,125,000 | $267,850,000 |
| % Margin | 69.6% | 74.7% | 75.4% | 74.1% |
| EBITDA | $91,540,000 | $178,435,000 | $161,896,000 | $123,620,000 |
| % Margin | 18.8% | 35.5% | 36.2% | 34.2% |
| Net Income | $50,047,000 | $127,977,000 | $112,723,000 | $80,519,000 |
| % Margin | 10.3% | 25.5% | 25.2% | 22.3% |
| EPS Diluted | 35.47 | 88.87 | 76.92 | 54.05 |
| % Growth | -60.1% | 15.5% | 42.3% | – |
| Operating Cash Flow | $82,459,000 | $110,660,000 | $159,610,000 | $61,829,000 |
| Capital Expenditures | -$7,990,000 | -$20,829,000 | -$14,497,000 | -$12,277,000 |
| Free Cash Flow | $74,469,000 | $89,831,000 | $145,113,000 | $49,552,000 |